Novel monoclonal antibodies against the C-terminal HEAT domain of huntingtin
Journal of Huntington's Disease · 2026
DOI: 10.1177/18796397261426634 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Huntington's Disease, 2026. Verfasst von Yang-Nim Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Developmental Studies Hybridoma Bank, Department of Biology, The University of Iowa, 028 BBE, Iowa City, IA 52242-1324, USA. Hauptthemen laut MEDLINE: Huntingtin Protein, Antibodies, Monoclonal, Huntington Disease. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Hereditary Disease Foundation, Natural Sciences and Engineering Research Council of Canada, Schrödinger, LLC.
Abstract (Originalsprache)
Background
Reliable detection of huntingtin (HTT) is essential for understanding Huntington's disease (HD) biology and for evaluating therapeutic strategies. However, high-quality monoclonal antibodies (mAbs) against the HTT C-terminal domain remain limited.
Objective
We sought to generate and validate novel monoclonal antibodies targeting the HTT C-terminal HEAT-containing domain to better detect HTT independently of potential effects of polyglutamine length that can impact some N-terminally targeted antibodies.
Methods
We immunized mice with a highly purified, well-characterized recombinant protein corresponding to the HTT C-terminal domain. We generated monoclonal antibody-producing hybridoma cell lines and characterized the antibodies in common immuno-applications using parental and HTT-knockout cell lines, and in patient-derived fibroblasts.
Results
Three novel, independent hybridoma lines producing anti-HTT monoclonal antibodies were derived. Using CRISPR-edited HTT knockout cell lines and in patient-derived cells, we identified one clone, anti-HTT [2F8], that was specific and effective across Western blot, immunofluorescence, and ELISA assays. All antibodies bound full-length HTT irrespective of HAP40 interaction or polyQ length in vitro and in cells and showed no cross-reactivity to the N-terminal HEAT domain.
Conclusions
These C-terminal HTT mAbs are thus valuable additional tools for studying endogenous HTT function in both normal and disease contexts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Developmental Studies Hybridoma Bank, Department of Biology, The University of Iowa, 028 BBE, Iowa City, IA 52242-1324, USA.
- Structural Genomics Consortium, University of Toronto, Toronto, ON M5G 1L7, Canada.
- Department of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
- Department of Medical Biophysics, University of Toronto, Toronto, ON M5S 1A8, Canada.
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
- Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
ORCID-Profile: Rebeka Fanti, Samira Sadeghi, Renu Chandrasekaran, Douglas W Houston
Förderung
- Hereditary Disease Foundation
- Natural Sciences and Engineering Research Council of Canada
- Schrödinger, LLC
- NIH/ORIP
- CIHR
- Connaught Fund
Zitieren
APA
Park, Y. N., Fanti, R., Sadeghi, S., Chandrasekaran, R., Edwards, A. M., Harding, R. J., & Houston, D. W. (2026). Novel monoclonal antibodies against the C-terminal HEAT domain of huntingtin. Journal of Huntington's Disease. https://doi.org/10.1177/18796397261426634
Vancouver
Park YN, Fanti R, Sadeghi S, Chandrasekaran R, Edwards AM, Harding RJ, et al. Novel monoclonal antibodies against the C-terminal HEAT domain of huntingtin. Journal of Huntington's Disease. 2026. doi:10.1177/18796397261426634
BibTeX
@article{Park2026,
author = {Park, Yang-Nim and Fanti, Rebeka and Sadeghi, Samira and Chandrasekaran, Renu and Edwards, Aled M and Harding, Rachel J and Houston, Douglas W},
title = {Novel monoclonal antibodies against the C-terminal HEAT domain of huntingtin},
journal = {Journal of Huntington's Disease},
year = {2026},
doi = {10.1177/18796397261426634}
}
EUVIMED